Why Is LYCIA THERAPEUTICS I (LYCA) Stock Up Today?
By the Top Tier Newswire AI Desk · November 17, 2026 at 9:45 AM ET · reviewed against 10 wire stories
LYCIA THERAPEUTICS I (LYCA) is up +6.12% in the latest session. Our newswire has captured 10 stories on LYCA across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Lycia Therapeutics (LYCA) shares rose 6.12% to $30.36 as a wave of new analyst coverage initiated positive ratings on the stock. The primary driver was the simultaneous launch of coverage by multiple investment banks, which signaled strong institutional interest in the company’s food allergy franchise.
What Happened
Jefferies initiated coverage of Lycia Therapeutics with an Outperform rating and a price target of $50. Guggenheim also started coverage with a Buy rating, citing the potential of the food allergy market. TD Cowen initiated the stock with a Buy rating, while Evercore ISI assigned an Outperform rating. LifeSci Capital also initiated coverage with an Outperform rating. This cluster of positive initiations represents a significant shift in analyst attention for the company.
What The Data Shows
The stock opened at $28.62 and reached a session high of $31.29 at 9:30 AM ET before settling at $29.75. Volume so far is reported at 0.0M shares. The company has a market capitalization of $1.8B and trades within a 52-week range of $22.19 to $36.49. Over the last 8 sessions, the stock moved down 0.7%, declining from $28.80 to $28.61. However, the stock printed three fresh 52-week highs on 2026-11-17. Recent insider activity shows Venrock Healthcare Capital Partners Iii, L.P. bought shares on 2026-11-02, 2026-10-28, and 2026-10-23. In the last 90 days, there were 3 buys totaling $38.5M and 0 sells, with the most recent filing on 2026-11-04.
What To Watch
Lycia Therapeutics is scheduled to present at the 2026 Jefferies Global Healthcare Conference. Investors may monitor how the new price targets from Jefferies, Guggenheim, and TD Cowen are received in the coming sessions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
LYCA · Nov 17 session (5-min) · +7.69% vs prior close · updated 8:46 PM ETAI sentiment, last 36h · averaged over 10 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoGuruFocusBULLISH 61Analyst
LYCA Initiated by Jefferies -- Price Target Announced at $50
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with an Outperform at LifeSci Capital
3d agoThe FlyBULLISH 64Analyst
Guggenheim starts Lycia Therapeutics with a Buy on food allergy market potential
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with a Buy at Guggenheim
3d agoInvesting.com Analyst RatingsBULLISH 63Analyst
Guggenheim initiates Lycia Therapeutics stock with buy rating
Guggenheim initiates Lycia Therapeutics stock with buy rating
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with a Buy at TD Cowen
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with a Buy at Jefferies
3d agoThe FlyBULLISH 63Analyst
Lycia Therapeutics initiated with an Outperform at Evercore ISI
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →